Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Dayong Jin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1046-2666; OpenAlex author ID A5100633582. Sources: OpenAlex.

Their work

Papers
30 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
69
Papers, trials and grants by year

2012: 4 papers · 2013: 5 papers · 2014: 1 paper · 2015: 2 papers · 2016: 4 papers · 2017: 2 papers · 2018: 1 paper · 2019: 4 papers · 2020: none · 2021: 3 papers · 2022: 3 papers · 2023: none · 2024: 1 paper

Papers 30

  1. Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial. Co-author DOI 10.3892/ol.2024.14293↗
  2. GFAT1 is highly expressed in cancer stem cells of pancreatic cancer. Co-author DOI 10.21037/atm-22-1946↗
  3. Prognostic Effect of Age in Resected Pancreatic Cancer Patients: A Propensity Score Matching Analysis. Co-author DOI 10.3389/fonc.2022.789351↗
  4. PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.61498↗
  5. Prognostic value of preoperative glucose to lymphocyte ratio in patients with resected pancreatic cancer. Co-author DOI 10.1007/s10147-020-01782-y↗
  6. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic c… Co-author DOI 10.1038/s41419-021-04293-4↗
  7. The long non-coding RNA DKFZp434J0226 regulates the alternative splicing process through phosphorylation of SF3B6 in PDAC. Co-author DOI 10.1186/s10020-021-00347-7↗
  8. Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway. Co-author DOI 10.1016/j.canlet.2019.06.013↗
  9. Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score matching analysis. Co-author DOI 10.1186/s40880-019-0410-8↗
  10. Downregulated expression of RACK1 results in pancreatic cancer growth and metastasis. Co-author DOI 10.2147/ott.s176101↗
  11. Independent effect of postoperative neutrophil-to-lymphocyte ratio on the survival of pancreatic ductal adenocarcinoma with open distal pancreatosplenectomy an… Co-author DOI 10.7150/jca.35856↗
  12. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer. Co-author DOI 10.1186/s12967-018-1673-6↗
  13. Combination of preoperative CEA and CA19-9 improves prediction outcomes in patients with resectable pancreatic adenocarcinoma: results from a large follow-up c… Co-author DOI 10.2147/ott.s116136↗
  14. Moscatilin induces apoptosis of pancreatic cancer cells via reactive oxygen species and the JNK/SAPK pathway. Last author DOI 10.3892/mmr.2017.6144↗
  15. Low intratumoral regulatory T cells and high peritumoral CD8(+) T cells relate to long-term survival in patients with pancreatic ductal adenocarcinoma after pa… Co-author DOI 10.1007/s00262-015-1775-4↗
  16. ITRAQ-based quantitative proteomics reveals apolipoprotein A-I and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma. Last author DOI 10.1097/md.0000000000004527↗
  17. Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models. Co-author DOI 10.1097/mpa.0000000000000501↗
  18. Increased expression of αTubulin is associated with poor prognosis in patients with pancreatic cancer after surgical resection. Co-author DOI 10.18632/oncotarget.10630↗
  19. Long-term survival following total pancreatectomy and superior mesenteric-portal vein resection for pancreatic ductal adenocarcinoma: A case report. Last author DOI 10.3892/ol.2014.2628↗
  20. LIN28B suppresses microRNA let-7b expression to promote CD44+/LIN28B+ human pancreatic cancer stem cell proliferation and invasion. Co-author PMID 26609473↗
  21. TRAF6 is over-expressed in pancreatic cancer and promotes the tumorigenicity of pancreatic cancer cells. Co-author DOI 10.1007/s12032-014-0260-9↗
  22. Lipocalin-2 is associated with a good prognosis and reversing epithelial-to-mesenchymal transition in pancreatic cancer. First author DOI 10.1007/s00268-013-2009-6↗
  23. Lactate dehydrogenase A is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Co-author DOI 10.1007/s13277-013-0679-1↗
  24. Identification of proteins implicated in the development of pancreatic cancer-associated diabetes mellitus by iTRAQ-based quantitative proteomics. Co-author DOI 10.1016/j.jprot.2013.03.031↗
  25. iTRAQ-based quantitative proteomics reveals myoferlin as a novel prognostic predictor in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.jprot.2013.06.032↗
  26. Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer. Co-author DOI 10.1158/1940-6207.capr-12-0307↗
  27. Treatment of pancreatic cancer using an oncolytic virus harboring the lipocalin-2 gene. Co-author DOI 10.1002/cncr.27535↗
  28. A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer. Co-author DOI 10.1007/s10238-011-0159-0↗
  29. IRF-2 is over-expressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Last author DOI 10.1007/s13277-011-0273-3↗
  30. Primary small cell carcinoma of the pancreas: rare type of pancreatic cancer and review of the literatures. Last author DOI 10.1186/1477-7819-10-32↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dansong Wang · 21 shared papers, 2012–2024 · strength 1.78
  2. Wenchuan Wu · 16 shared papers, 2012–2024 · strength 1.42
  3. Tiantao Kuang · 14 shared papers, 2012–2024 · strength 1.40
  4. Xuefeng Xu · 12 shared papers, 2015–2024 · strength 1.32
  5. Wenhui Lou · 10 shared papers, 2012–2024 · strength 0.81
  6. Yefei Rong · 11 shared papers, 2012–2024 · strength 0.79
  7. Wenhui Lou · 7 shared papers, 2012–2022 · strength 0.69
  8. Yaolin Xu · 3 shared papers, 2021–2024 · strength 0.45
  9. Wenhui Lou · 6 shared papers, 2013–2022 · strength 0.43
  10. Ning Pu · 4 shared papers, 2018–2021 · strength 0.37
  11. Hanlin Yin · 4 shared papers, 2018–2021 · strength 0.37
  12. Lei Zhang · 3 shared papers, 2015–2022 · strength 0.32
  13. Yueming Zhang · 2 shared papers, 2021–2022 · strength 0.30
  14. Weilin Mao · 2 shared papers, 2019–2022 · strength 0.25
  15. Deliang Fu · 2 shared papers, 2017–2024 · strength 0.22
  16. Yuan Ji Ma · 2 shared papers, 2016–2024 · strength 0.22
  17. Xinyu Qin · 3 shared papers, 2012–2021 · strength 0.21
  18. Yuan Fang · 2 shared papers, 2017–2019 · strength 0.18
  19. Hanxing Tong · 2 shared papers, 2015–2021 · strength 0.18
  20. Zhe Wang · 1 shared paper, 2022 · strength 0.16
  21. Lie Yao · 1 shared paper, 2024 · strength 0.16
  22. Tianshu Liu · 1 shared paper, 2024 · strength 0.16
  23. Xi Guo · 1 shared paper, 2024 · strength 0.16
  24. Lili Wu · 1 shared paper, 2024 · strength 0.16
  25. Wenquan Wang · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.